Epix resubmits Vasovist NDA

By AuntMinnie.com staff writers

July 1, 2008 -- MRI contrast developer Epix Pharmaceuticals of Lexington, MA, has resubmitted a new drug application (NDA) for its MR angiography (MRA) contrast agent, Vasovist (gadofosveset trisodium).

Vasovist is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through MRA.

The agent has been approved for marketing in 33 countries, including the European Union, Switzerland, Turkey, Australia, and Canada. If approved in the U.S., Vasovist would become the first contrast agent in the country for use with MRA.